ClinicalTrials.gg
TerminatedNCT03362502Updated Sep 15, 2025Results posted

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

A Phase 1 interventional study of PF-06939926 in Duchenne Muscular Dystrophy, sponsored by Pfizer. Terminated at 22 sites in United States. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
4 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
91st of 172
23 · median 25
Started
2018
with 20 others
Phase 1
32 of 233
3 open now
Registered
118th of 233
by date
Lead sponsor
7 of 233
Pfizer

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 91st largest by enrollment of the 172 interventional ones that give a count, is one of 21 that started in 2018, is one of 32 in phase 1, and was the 118th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 4 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives include measurement of dystrophin expression and distribution, and assessments of muscle strength, quality, and function.

A total of approximately 22 subjects will receive PF-06939926, and these will include both ambulatory and non-ambulatory subjects. Up to 13 subjects may be included in a cohort that includes the concomitant medication, sirolimus. In order to mitigate unanticipated risks to subject safety, enrollment will be staggered within and between two planned dose-levels and will include a formal review by an external data monitoring committee (E-DMC) prior to dose progression.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • gene therapy
  • mini-dystrophin
  • AAV
  • fordadistrogene movaparvovec
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age as follows, based on ambulatory status:

    • FOR AMBULATORY PARTICIPANTS, defined as the ability to walk at least 10 meters unassisted: Between 4 and 12 years, inclusive,
    • FOR NON-AMBULATORY PARTICIPANTS, defined as the inability to walk at least 10 meters unassisted: No age restrictions so long as loss of ambulation occurs prior to the subject's 17th birthday;
  • Diagnosis of Duchenne muscular dystrophy confirmed by medical history and genetic testing;
  • Receipt of for 6 months and a stable daily dose for at least 3 months prior to study entry;
  • Ability to tolerate magnetic resonance imaging (MRI) without sedation and with no to these procedures;
  • Ability to tolerate muscle under anesthesia with no contraindications to these procedures;
  • Body weights as follows, based on ambulatory status:

    • FOR AMBULATORY PARTICIPANTS: Between 15 kg and 50 kg,
    • FOR NON-AMBULATORY PARTICIPANTS: Less than 75 kg, but which may be managed or adjusted to a lower limit, especially to ensure participant safety;
  • Functional performance as follows, based on ambulatory status:

    • FOR AMBULATORY PARTICIPANTS: Ability to rise from floor within seven (7) seconds,
    • FOR NON-AMBULATORY PARTICIPANTS: Percent predicted forced vital capacity greater than 40% as part of pulmonary function tests, as well as adequate upper limb function.

Exclusion Criteria:

  • Receipt of within 3 months prior to receiving PF-06939926 or exposure to an influenza (or other inactivated) vaccination or systemic antiviral and/or interferon therapy within 30 days prior to receipt of PF-06939926;
  • Prior exposure to any gene therapy agent, including exon-skipping agents;
  • Exposure to other drugs within 30 days or 5 half-lives, whichever is longer;
  • Neutralizing antibodies (NAb) against adeno-associated virus, serotype 9 (AAV9);
  • Compromised cardiac function as indicated by on cardiac MRI, as follows, based on ambulatory status:

    • FOR AMBULATORY PARTICIPANTS: Less than 55%,
    • FOR NON-AMBULATORY PARTICIPANTS: Less than 35%;
  • Inadequate hepatic or renal function or risk factors for disease on screening laboratory assessments.
  • The following genetic abnormalities in the dystrophin gene as confirmed by the investigator based on the review of the DMD genetic testing:

    1. Any mutation (exon deletion, exon duplication, insertion, or point mutation) affecting any exon between exon 9 and exon 13, inclusive; OR
    2. A deletion that affects both exon 29 and exon 30.

Sirolimus Cohort

Inclusion Criteria

  • > 8 years of age Exclusion Criteria
  • to sirolimus or intolerance to soy, including a history of angioedema
  • Concomitant use with strong /P-gp inducers or inhibitors
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    PF-06939926

    Genetic: PF-06939926

Interventions

  • GeneticPF-06939926

    Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter. Subjects will receive a single intravenous infusion of one of 2 dose levels.

06

What researchers measure

Primary outcomes

  1. Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a treatment-emergent AE (TEAE). A serious AE (SAE) was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  2. Number of Participants With All-Causality TEAEs by System Organ Class (SOC) and Preferred Term (PT) for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to Medical Dictionary for Regulatory Activities (MedDRA) version 25.0 SOC and PT.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  3. Number of Participants With Treatment-Related TEAEs for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  4. Number of Participants With Treatment-Related TEAEs by SOC and PT for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs were determined by the investigator.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  5. Number of Participants With All-Causality SAEs by SOC and PT for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  6. Number of Participants With Treatment-Related SAEs by SOC and PT for 1-Year Follow-Up

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  7. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Hematology

    Following hematologic parameters were analyzed for laboratory examination: hemoglobin, hematocrit, red blood cell (RBC) count, platelet count, white blood cell count, total neutrophils, absolute neutrophils (ANC), eosinophils, monocytes, basophils, lymphocytes, red blood cell indices, and haptoglobin. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  8. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Clinical Chemistry

    Following parameters for clinical chemistry were analyzed for laboratory examination: blood urea nitrogen (BUN) and creatinine, glucose, calcium, sodium, potassium, chloride, total CO2 (bicarbonate), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (direct and indirect bilirubin), alkaline phosphatase, uric acid, albumin, total protein, serum phosphorus, cystatin C, creatine kinase, creatine kinase myocardial b fraction (CK-MB), amylase, lipase, gamma-glutamyl transferase (GGT), C-reactive protein (CRP), and cardiac troponin I. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  9. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Urinalysis

    Following parameters for urinalysis were analyzed for laboratory examination: pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  10. Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up

    Cardiac MRI was performed after thigh and upper limb MRI or on separate days within the required visit window. Change in LVEF is presented as percentages, and was calculated as \[(stroke volume) / (end-diastolic volume)\]\*100%. Baseline is defined as the last pre-dose measurement. Change from baseline on Day 360 (ie, 1 year post dose) was reported for this outcome measure.

    Time frame: Baseline, 1 year post dose of PF-06839926 (Day 360)

  11. Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up

    Triplicate ECG was performed after the participant had rested quietly for at least 10 minutes in a supine position. The pre-defined categorical criteria include PR interval aggregate (msec): value\>=300, baseline\>200 and percent change\>=25%, baseline\<=200 and percent change\>=50%; QRS duration aggregate (msec): value\>=140, percent change\>=50%; QTcF interval aggregate (msec): 450\<=value\<480, 480\<=value\<500, value\>=500, 30\<=change\<60, change\>=60. Only the category(ies) with at least 1 participant meeting the pre-defined criterion is/are reported for this outcome measure. Baseline for ECG was defined as the measurement before the Day 1 study drug administration.

    Time frame: Baseline up to 1 year post dose of PF-06939926

  12. Number of Participants With Positive Responses on Columbia-Suicide Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories

    C-SSRS is a participant rated questionnaire to assess whether participant experienced the following: completed suicide(1), suicide attempt(2)("Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4)("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior"). Yes/No responses are mapped to C-CASA categories. C-SSRS was conducted with the participant's care giver/legal guardian on the participant's behalf throughout the study for participants\<=12 years of age at screening. Baseline is defined as the last predose measurement. Number of participants with responses of "Yes" is reported for this outcome measure.

    Time frame: Baseline, Day 7, Day 14, Day 180, and Day 360

  13. Number of Participants With Vital Signs Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up

    Vital signs consisted of blood pressure, respiratory rate, and heart rate, was obtained with these measurements at the following timepoints: within 30 minutes before and approximately 30 minutes, 1, 2, 4, 8, and 24 hours after the start of the infusion, and on Days 4, 7, 10, 14, 30, 90, 180, and 360. Baseline was defined as the last pre-dose recording. Number of participants who had at least 1 vital sign measurement at the specified timepoints meeting the pre-defined criteria from baseline up to the end of 1-year follow-up is reported for this outcome measure.

    Time frame: Baseline up to 1 year post dose of PF-06939926

07

Results

Posted Sep 20, 2024

Participant flow

The study reached its primary completion date (PCD) on 28 Mar 2022. The data cutoff for PCD was on 30 Sep 2022. As of 30 Sep 2022, a total of 22 participants, including 19 ambulatory participants and 3 non-ambulatory participants, were enrolled and assigned to treatment.

Participant flow — Overall Study
MilestonePF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Started3163
Completed3162
Not completed001
Withdrew: Death001

Outcome measures

PrimaryNumber of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a treatment-emergent AE (TEAE). A serious AE (SAE) was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
TEAEs3163
SAEs032
Severe AEs122
PrimaryNumber of Participants With All-Causality TEAEs by System Organ Class (SOC) and Preferred Term (PT) for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to Medical Dictionary for Regulatory Activities (MedDRA) version 25.0 SOC and PT.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With All-Causality TEAEs by System Organ Class (SOC) and Preferred Term (PT) for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total291
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Anaemia020
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolysis010
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome001
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Leukocytosis100
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Lymphopenia100
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia090
SOC: CARDIAC DISORDERS, Total002
SOC: CARDIAC DISORDERS, PT: Cardiogenic shock001
SOC: CARDIAC DISORDERS, PT: Cardiomyopathy001
SOC: ENDOCRINE DISORDERS, Total010
SOC: ENDOCRINE DISORDERS, PT: Androgen deficiency010
SOC: EYE DISORDERS, Total001
SOC: EYE DISORDERS, PT: Lacrimation increased001
SOC: GASTROINTESTINAL DISORDERS, Total3153
SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain010
SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain lower010
SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain upper032
SOC: GASTROINTESTINAL DISORDERS, PT: Constipation030
SOC: GASTROINTESTINAL DISORDERS, PT: Diarrhoea030
SOC: GASTROINTESTINAL DISORDERS, PT: Gastrooesophageal reflux disease010
SOC: GASTROINTESTINAL DISORDERS, PT: Inguinal hernia100
SOC: GASTROINTESTINAL DISORDERS, PT: Nausea283
SOC: GASTROINTESTINAL DISORDERS, PT: Toothache100
SOC: GASTROINTESTINAL DISORDERS, PT: Vomiting2133
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, Total2111
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Chest pain001
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Fatigue160
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Infusion site reaction010
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Mass010
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Pyrexia180
SOC: HEPATOBILIARY DISORDERS, Total021
SOC: HEPATOBILIARY DISORDERS, PT: Liver injury021
SOC: INFECTIONS AND INFESTATIONS, Total071
SOC: INFECTIONS AND INFESTATIONS, PT: Cellulitis010
SOC: INFECTIONS AND INFESTATIONS, PT: Conjunctivitis010
SOC: INFECTIONS AND INFESTATIONS, PT: Influenza010
SOC: INFECTIONS AND INFESTATIONS, PT: Molluscum contagiosum010
SOC: INFECTIONS AND INFESTATIONS, PT: Nasopharyngitis020
SOC: INFECTIONS AND INFESTATIONS, PT: Parainfluenzae virus infection001
SOC: INFECTIONS AND INFESTATIONS, PT: Sinusitis030
SOC: INFECTIONS AND INFESTATIONS, PT: Tooth abscess010
SOC: INFECTIONS AND INFESTATIONS, PT: Urinary tract infection001
SOC: INFECTIONS AND INFESTATIONS, PT: Viral upper respiratory tract infection010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, Total061
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Contusion010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Fall050
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Joint dislocation010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Joint injury010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Ligament sprain010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Post procedural contusion010
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Procedural pain001
SOC: INJURY, POISONING AND PROCEDURAL COMPLICATIONS, PT: Skin abrasion010
SOC: INVESTIGATIONS, Total062
SOC: INVESTIGATIONS, PT: Amylase increased010
SOC: INVESTIGATIONS, PT: Complement factor C4 decreased050
SOC: INVESTIGATIONS, PT: Cystatin C increased010
SOC: INVESTIGATIONS, PT: Glutamate dehydrogenase increased030
SOC: INVESTIGATIONS, PT: Hepatic enzyme increased001
SOC: INVESTIGATIONS, PT: Lipase increased010
SOC: INVESTIGATIONS, PT: Troponin increased001
SOC: METABOLISM AND NUTRITION DISORDERS, Total280
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Decreased appetite260
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration050
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Hyperuricaemia010
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, Total232
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Arthralgia002
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Back pain001
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Myalgia010
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Osteopenia100
SOC: MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, PT: Pain in extremity110
SOC: NERVOUS SYSTEM DISORDERS, Total273
SOC: NERVOUS SYSTEM DISORDERS, PT: Dizziness100
SOC: NERVOUS SYSTEM DISORDERS, PT: Headache073
SOC: NERVOUS SYSTEM DISORDERS, PT: Lethargy100
SOC: NERVOUS SYSTEM DISORDERS, PT: Migraine010
SOC: PSYCHIATRIC DISORDERS, Total230
SOC: PSYCHIATRIC DISORDERS, PT: Abnormal behaviour010
SOC: PSYCHIATRIC DISORDERS, PT: Affect lability110
SOC: PSYCHIATRIC DISORDERS, PT: Anxiety010
SOC: PSYCHIATRIC DISORDERS, PT: Irritability010
SOC: PSYCHIATRIC DISORDERS, PT: Mood altered100
SOC: PSYCHIATRIC DISORDERS, PT: Suicidal ideation010
SOC: RENAL AND URINARY DISORDERS, Total040
SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury010
SOC: RENAL AND URINARY DISORDERS, PT: Chronic kidney disease010
SOC: RENAL AND URINARY DISORDERS, PT: Glycosuria010
SOC: RENAL AND URINARY DISORDERS, PT: Haematuria020
SOC: RENAL AND URINARY DISORDERS, PT: Ketonuria020
SOC: RENAL AND URINARY DISORDERS, PT: Proteinuria020
SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, Total040
SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Cough020
SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Epistaxis010
SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Oropharyngeal pain010
SOC: RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, PT: Rhinorrhoea010
SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, Total031
SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Ecchymosis001
SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Rash020
SOC: SKIN AND SUBCUTANEOUS TISSUE DISORDERS, PT: Urticaria010
SOC: VASCULAR DISORDERS, Total020
SOC: VASCULAR DISORDERS, PT: Hypertension020
PrimaryNumber of Participants With Treatment-Related TEAEs for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Severe AE=an event that prevents normal everyday activities. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
TEAEs3153
SAEs032
Severe AEs022
PrimaryNumber of Participants With Treatment-Related TEAEs by SOC and PT for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs were determined by the investigator.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs by SOC and PT for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total291
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Anaemia020
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolysis010
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome001
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Leukocytosis100
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Lymphopenia100
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia090
SOC: CARDIAC DISORDERS, Total001
SOC: CARDIAC DISORDERS, PT: Cardiogenic shock001
SOC: GASTROINTESTINAL DISORDERS, Total2153
SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain010
SOC: GASTROINTESTINAL DISORDERS, PT: Abdominal pain upper031
SOC: GASTROINTESTINAL DISORDERS, PT: Diarrhoea010
SOC: GASTROINTESTINAL DISORDERS, PT: Nausea283
SOC: GASTROINTESTINAL DISORDERS, PT: Vomiting2133
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, Total2110
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Fatigue160
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Infusion site reaction010
SOC: GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS, PT: Pyrexia180
SOC: HEPATOBILIARY DISORDERS, Total021
SOC: HEPATOBILIARY DISORDERS, PT: Liver injury021
SOC: INVESTIGATIONS, Total062
SOC: INVESTIGATIONS, PT: Amylase increased010
SOC: INVESTIGATIONS, PT: Complement factor C4 decreased050
SOC: INVESTIGATIONS, PT: Cystatin C increased010
SOC: INVESTIGATIONS, PT: Glutamate dehydrogenase increased030
SOC: INVESTIGATIONS, PT: Hepatic enzyme increased001
SOC: INVESTIGATIONS, PT: Lipase increased010
SOC: INVESTIGATIONS, PT: Troponin increased001
SOC: METABOLISM AND NUTRITION DISORDERS, Total280
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Decreased appetite260
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration050
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Hyperuricaemia010
SOC: NERVOUS SYSTEM DISORDERS, Total213
SOC: NERVOUS SYSTEM DISORDERS, PT: Dizziness100
SOC: NERVOUS SYSTEM DISORDERS, PT: Headache013
SOC: NERVOUS SYSTEM DISORDERS, PT: Lethargy100
SOC: RENAL AND URINARY DISORDERS, Total040
SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury010
SOC: RENAL AND URINARY DISORDERS, PT: Chronic kidney disease010
SOC: RENAL AND URINARY DISORDERS, PT: Glycosuria010
SOC: RENAL AND URINARY DISORDERS, PT: Haematuria020
SOC: RENAL AND URINARY DISORDERS, PT: Ketonuria020
SOC: RENAL AND URINARY DISORDERS, PT: Proteinuria020
SOC: VASCULAR DISORDERS, Total020
SOC: VASCULAR DISORDERS, PT: Hypertension020
PrimaryNumber of Participants With All-Causality SAEs by SOC and PT for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With All-Causality SAEs by SOC and PT for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total011
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome001
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia010
SOC: CARDIAC DISORDERS, Total001
SOC: CARDIAC DISORDERS, PT: Cardiogenic shock001
SOC: INFECTIONS AND INFESTATIONS, Total001
SOC: INFECTIONS AND INFESTATIONS, PT: Urinary tract infection001
SOC: METABOLISM AND NUTRITION DISORDERS, Total010
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration010
SOC: RENAL AND URINARY DISORDERS, Total010
SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury010
PrimaryNumber of Participants With Treatment-Related SAEs by SOC and PT for 1-Year Follow-Up

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Any AE that started following start of treatment of PF-06939926 was counted as a TEAE. An SAE was an untoward medical occurrence that resulted in death, was life-threatening (immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect, or was considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-related AEs and SAEs were determined by the investigator. For this outcome measure, TEAEs were reported according to MedDRA version 25.0 SOC and PT.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related SAEs by SOC and PT for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, Total011
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Haemolytic uraemic syndrome001
SOC: BLOOD AND LYMPHATIC SYSTEM DISORDERS, PT: Thrombocytopenia010
SOC: CARDIAC DISORDERS, Total001
SOC: CARDIAC DISORDERS, PT: Cardiogenic shock001
SOC: METABOLISM AND NUTRITION DISORDERS, Total010
SOC: METABOLISM AND NUTRITION DISORDERS, PT: Dehydration010
SOC: RENAL AND URINARY DISORDERS, Total010
SOC: RENAL AND URINARY DISORDERS, PT: Acute kidney injury010
PrimaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Hematology

Following hematologic parameters were analyzed for laboratory examination: hemoglobin, hematocrit, red blood cell (RBC) count, platelet count, white blood cell count, total neutrophils, absolute neutrophils (ANC), eosinophils, monocytes, basophils, lymphocytes, red blood cell indices, and haptoglobin. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Hematology
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Hemoglobin (g/dL) <0.8x Lower Limit of Normal (LLN)011
Hematocrit (%)<0.8x LLN021
Erythrocytes (10^6/mm3)<0.8x LLN011
Platelets (10^3/mm3)<0.5x LLN051
Erythrocyte Cell Morphology (No Unit)>0011
Leukocytes (10^3/mm3)>1.5x Upper Limit of Normal (ULN)021
Lymphocytes (10^3/mm3)<0.8x LLN162
Lymphocytes (10^3/mm3)>1.2x ULN021
Lymphocytes Atypical (10^3/mm3)>0192
Neutrophils (10^3/mm3)<0.8x LLN020
Neutrophils (10^3/mm3)>1.2x ULN172
Neutrophils Band Form (10^3/mm3)>0.27—01
Basophils (10^3/mm3)>1.2x ULN010
Eosinophils (10^3/mm3)>1.2x ULN120
Monocytes (10^3/mm3)>1.2x ULN0123
Activated Partial Thromboplastin Time (sec)>1.1x ULN110
Prothrombin Time (sec)>1.1x ULN172
Neutrophils -TOTAL COUNT (10^3/mm3)<1.35020
Neutrophils -TOTAL COUNT (10^3/mm3)>8.152142
Myelocytes (10^3/mm3)>0—1—
Haptoglobin (mg/dL)<30—31
Haptoglobin (mg/dL)>2000103
PrimaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Clinical Chemistry

Following parameters for clinical chemistry were analyzed for laboratory examination: blood urea nitrogen (BUN) and creatinine, glucose, calcium, sodium, potassium, chloride, total CO2 (bicarbonate), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (direct and indirect bilirubin), alkaline phosphatase, uric acid, albumin, total protein, serum phosphorus, cystatin C, creatine kinase, creatine kinase myocardial b fraction (CK-MB), amylase, lipase, gamma-glutamyl transferase (GGT), C-reactive protein (CRP), and cardiac troponin I. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Clinical Chemistry
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Bilirubin (mg/dL)>1.5x ULN001
Direct Bilirubin (mg/dL)>1.5x ULN001
Aspartate Aminotransferase (U/L)>3.0x ULN3163
Alanine Aminotransferase (U/L)>3.0x ULN3163
Gamma Glutamyl Transferase (U/L)>3.0x ULN011
Protein (g/dL)<0.8x LLN020
Albumin (g/dL)<0.8x LLN001
Urea Nitrogen (mg/dL)>1.3x ULN011
Creatinine (mg/dL)>1.3x ULN011
Urate (mg/dL)>1.2x ULN060
Sodium (mEq/L)<0.95x LLN012
Potassium (mEq/L)<0.9x LLN011
Calcium (mg/dL)<0.9x LLN001
Phosphate (mg/dL)<0.8x LLN021
Bicarbonate (mEq/L)<0.9x LLN022
Bicarbonate (mEq/L)>1.1x ULN010
Glucose (mg/dL)>1.5x ULN042
Creatine Kinase (U/L)>2.0x ULN3163
Triacylglycerol Lipase (U/L)>1.5x ULN001
C-Reactive Protein High Sens (mg/dL)>1.1x ULN032
Cystatin C (mg/L)>1.2x ULN031
Creatine Kinase MB (ug/L)>2.0x ULN3162
Glutamate Dehydrogenase (U/L)>1.0x ULN2103
Glutamate Dehydrogenase (U/L)>2.0x ULN052
Glutamate Dehydrogenase (U/L)>3.0x ULN032
Ferritin (ng/mL)<23.9080
Ferritin (ng/mL)>336.20113
PrimaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Urinalysis

Following parameters for urinalysis were analyzed for laboratory examination: pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy. Laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last pre-dose measurement.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Urinalysis
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
URINE Ketones (No Unit)>=1073
URINE Protein (Scalar)>=1021
URINE Hemoglobin (No Unit)>=1041
URINE Nitrite (No Unit)>=1010
URINE Erythrocytes (/high-powered field [HPF])>=20010
URINE Leukocytes (/HPF)>=20—10
Granular Casts (/low-power field [LPF])>1—1—
Hyaline Casts (/LPF)>1—1—
Uric Acid Crystals (/LPF)>=0.5—2—
Calcium Oxalate Crystals (/LPF)>=0.5221
Amorphous Crystals (/LPF)>=0.5071
Urine Microscopic Exam (Scalar)>=12143
PrimaryChange From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up

Cardiac MRI was performed after thigh and upper limb MRI or on separate days within the required visit window. Change in LVEF is presented as percentages, and was calculated as \[(stroke volume) / (end-diastolic volume)\]\*100%. Baseline is defined as the last pre-dose measurement. Change from baseline on Day 360 (ie, 1 year post dose) was reported for this outcome measure.

Time frame:
Baseline, 1 year post dose of PF-06839926 (Day 360)
Reported as:
Mean · Percentage
Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up
PercentagePF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up-0.7 ± 3.2-1.0 ± 4.3-3.1 ± 1.8
PrimaryNumber of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up

Triplicate ECG was performed after the participant had rested quietly for at least 10 minutes in a supine position. The pre-defined categorical criteria include PR interval aggregate (msec): value\>=300, baseline\>200 and percent change\>=25%, baseline\<=200 and percent change\>=50%; QRS duration aggregate (msec): value\>=140, percent change\>=50%; QTcF interval aggregate (msec): 450\<=value\<480, 480\<=value\<500, value\>=500, 30\<=change\<60, change\>=60. Only the category(ies) with at least 1 participant meeting the pre-defined criterion is/are reported for this outcome measure. Baseline for ECG was defined as the measurement before the Day 1 study drug administration.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up120
PrimaryNumber of Participants With Positive Responses on Columbia-Suicide Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories

C-SSRS is a participant rated questionnaire to assess whether participant experienced the following: completed suicide(1), suicide attempt(2)("Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4)("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior"). Yes/No responses are mapped to C-CASA categories. C-SSRS was conducted with the participant's care giver/legal guardian on the participant's behalf throughout the study for participants\<=12 years of age at screening. Baseline is defined as the last predose measurement. Number of participants with responses of "Yes" is reported for this outcome measure.

Time frame:
Baseline, Day 7, Day 14, Day 180, and Day 360
Reported as:
Count of participants · Participants
Number of Participants With Positive Responses on Columbia-Suicide Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Baseline: Lifetime <1> Completed Suicide000
Baseline: Lifetime <2> Suicide Attempt000
Baseline: Lifetime <3> Preparatory Acts towards Imminent Suicidal Behavior000
Baseline: Lifetime <4> Suicidal Ideation010
Baseline: Lifetime <7> Self-injurious behavior, no suicidal intent000
Baseline: Since Last Visit <1> Completed Suicide000
Baseline: Since Last Visit <2> Suicide Attempt000
Baseline: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior000
Baseline: Since Last Visit <4> Suicidal Ideation000
Baseline: Since Last Visit <7> Self-injurious behavior, no suicidal intent000
Day 7: Since Last Visit <1> Completed Suicide000
Day 7: Since Last Visit <2> Suicide Attempt000
Day 7: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior000
Day 7: Since Last Visit <4> Suicidal Ideation000
Day 7: Since Last Visit <7> Self-injurious behavior, no suicidal intent000
Day 14: Since Last Visit <1> Completed Suicide000
Day 14: Since Last Visit <2> Suicide Attempt000
Day 14: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior000
Day 14: Since Last Visit <4> Suicidal Ideation000
Day 14: Since Last Visit <7> Self-injurious behavior, no suicidal intent000
Day 180: Since Last Visit <1> Completed Suicide000
Day 180: Since Last Visit <2> Suicide Attempt000
Day 180: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior000
Day 180: Since Last Visit <4> Suicidal Ideation001
Day 180: Since Last Visit <7> Self-injurious behavior, no suicidal intent000
Day 360: Since Last Visit <1> Completed Suicide000
Day 360: Since Last Visit <2> Suicide Attempt000
Day 360: Since Last Visit <3> Preparatory Acts towards Imminent Suicidal Behavior000
Day 360: Since Last Visit <4> Suicidal Ideation000
Day 360: Since Last Visit <7> Self-injurious behavior, no suicidal intent000
PrimaryNumber of Participants With Vital Signs Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up

Vital signs consisted of blood pressure, respiratory rate, and heart rate, was obtained with these measurements at the following timepoints: within 30 minutes before and approximately 30 minutes, 1, 2, 4, 8, and 24 hours after the start of the infusion, and on Days 4, 7, 10, 14, 30, 90, 180, and 360. Baseline was defined as the last pre-dose recording. Number of participants who had at least 1 vital sign measurement at the specified timepoints meeting the pre-defined criteria from baseline up to the end of 1-year follow-up is reported for this outcome measure.

Time frame:
Baseline up to 1 year post dose of PF-06939926
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up
ParticipantsPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Respiratory Rate: value<14 breaths/min for aged 6-12 years00—
Respiratory Rate: value>22 breaths/min for aged 6-12 years316—
Respiratory Rate: value<12 breaths/min for aged 13-18 years——0
Respiratory Rate: value>20 breaths/min for aged 13-18 years——3
Supine Diastolic Blood Pressure: value<50 mmHg150
Supine Diastolic Blood Pressure: increase>=20 mmHg020
Supine Diastolic Blood Pressure: decrease>=20 mmHg121
Supine Heart Rate: value<40 beats per minute (bpm)000
Supine Heart Rate: value>120 bpm011
Supine Systolic Blood Pressure: value<70 mmHg + 2*age for aged 2-10 years00—
Supine Systolic Blood Pressure: value<90 mmHg for aged 11 years and older—10
Supine Systolic Blood Pressure: increase from baseline>=30 mmHg050
Supine Systolic Blood Pressure: decrease from baseline>=30 mmHg100

Adverse events

Collected over Baseline up to the end of 1-year follow-up (approximately 360 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06939926: Low Dose, Ambulatory Cohort0/3 (0%)0/3 (0%)3/3 (100%)
PF-06939926: High Dose, Ambulatory Cohort0/16 (0%)3/16 (18.8%)16/16 (100%)
PF-06939926: High Dose, Non-Ambulatory Cohort1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
Haemolytic uraemic syndromeBlood and lymphatic system disorders0/30/161/3
Cardiogenic shockCardiac disorders0/30/161/3
Urinary tract infectionInfections and infestations0/30/161/3
ThrombocytopeniaBlood and lymphatic system disorders0/31/160/3
DehydrationMetabolism and nutrition disorders0/31/160/3
Acute kidney injuryRenal and urinary disorders0/31/160/3
Most frequent other events
Showing 10 of 80
Most frequent other events
EventPF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory Cohort
NauseaGastrointestinal disorders2/38/163/3
VomitingGastrointestinal disorders2/313/163/3
HeadacheNervous system disorders0/37/163/3
Abdominal pain upperGastrointestinal disorders0/33/162/3
Decreased appetiteMetabolism and nutrition disorders2/36/160/3
ArthralgiaMusculoskeletal and connective tissue disorders0/30/162/3
ThrombocytopeniaBlood and lymphatic system disorders0/38/160/3
PyrexiaGeneral disorders1/38/160/3
FatigueGeneral disorders1/36/160/3
LeukocytosisBlood and lymphatic system disorders1/30/160/3

Baseline characteristics

Includes all enrolled participants who received PF-06939926 as of the PCD data cutoff (30 Sep 2022). Participants were analyzed according to the intervention they actually received.

Age, Customized
Age, Customized(Participants)PF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory CohortTotal
6-<7 years0202
7-<8 years1405
8-<9 years1405
9-<10 years1405
10-<11 years0101
11-<12 years0000
>=12 years0134
Age, Customized
Age, Customized(Years)PF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory CohortTotal
Median8 (7 to 9)8 (6 to 12)14 (13 to 16)8 (6 to 16)
Sex: Female, Male
Sex: Female, Male(Participants)PF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory CohortTotal
Female0000
Male316322
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory CohortTotal
White313117
Black or African American0112
Asian0202
Not Reported0011
Mutation Type
Mutation Type(Participants)PF-06939926: Low Dose, Ambulatory CohortPF-06939926: High Dose, Ambulatory CohortPF-06939926: High Dose, Non-Ambulatory CohortTotal
Deletion1001
Exon Deletion17210
Exon Duplication0303
Insertion0101
Point Mutation1416
Cryptic Splice Donor Site0101
08

Study locations

22 sites
  • MRI Research Center
    Los Angeles, California 90095, United States
  • Reed Neurological Research Center
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center (Investigational Drug Section)
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center - Interventional Radiology
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center Drug Information Center
    Los Angeles, California 90095, United States
  • UCLA (David Geffen School of Medicine)
    Los Angeles, California 90095, United States
  • UCLA Children's Heart Center
    Los Angeles, California 90095, United States
  • UCLA Mattel Children's Hospital
    Los Angeles, California 90095, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • UCLA Outpatient Surgery Center
    Los Angeles, California 90095, United States
  • Duke Neurology
    Durham, North Carolina 27705, United States
  • Duke University Medical Center, Lenox Baker Children's Hospital
    Durham, North Carolina 27705, United States
  • Biospecimen Repository & Processing Core - BPRC
    Durham, North Carolina 27710, United States
  • Duke Cardiovascular Magnetic Resonance Center
    Durham, North Carolina 27710, United States
  • Duke Children's Hospital & Health Center
    Durham, North Carolina 27710, United States
  • Duke University Hospital Investigational Drug Services (IDS) Pharmacy
    Durham, North Carolina 27710, United States
  • CCTS Clinical Research Center
    Salt Lake City, Utah 84108, United States
  • University of Utah Imaging and Neurosciences Center
    Salt Lake City, Utah 84108, United States
  • University of Utah Hospital & Clinics Investigational Drug Services
    Salt Lake City, Utah 84112, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84112, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • University of Utah Clinical Neurosciences Center
    Salt Lake City, Utah 84132, United States
09

References and documents

Publications

  • Walsh J, Palandra J, Duriga N, Beidler D, McIntosh A, Binks M, Neubert H. Dystrophin/mini-dystrophin expression analysis by immunoaffinity liquid chromatography-tandem mass spectrometry after gene therapy for DMD. Gene Ther. 2025 Dec;32(6):573-580. doi: 10.1038/s41434-025-00554-5. Epub 2025 Aug 2. PubMed 40753271 ↗
  • Byrne BJ, Butterfield RJ, Shieh PB, Smith EC, Licht C, Binks M, Casinghino S, Delnomdedieu M, Ravindra KC, McDonnell T, Ryan K, Schulz M, Shen Q, Shi H, Sirivelu MP, Vaidya VS, Whiteley L, Levy DI. Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy. Mol Ther. 2025 Sep 3;33(9):4226-4238. doi: 10.1016/j.ymthe.2025.06.032. Epub 2025 Jun 28. PubMed 40583275 ↗
  • Sherlock SP, Levy DI, McIntosh A, Shieh PB, Smith EC, McDonnell TG, Ryan KA, Delnomdedieu M, Binks M, Lal AK, Butterfield RJ. Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial. Mol Ther. 2025 Sep 3;33(9):4216-4225. doi: 10.1016/j.ymthe.2025.06.031. Epub 2025 Jun 28. PubMed 40583273 ↗
  • Butterfield RJ, Shieh PB, Li H, Binks M, McDonnell TG, Ryan KA, Delnomdedieu M, Belluscio BA, Neelakantan S, Levy DI, Schwartz PF, Smith EC. AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial. Nat Med. 2025 Aug;31(8):2712-2721. doi: 10.1038/s41591-025-03750-3. Epub 2025 Jun 27. PubMed 40579547 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Mar 2022, 50 months.

Results were first posted in Sep 2024, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 5, 2017
StartActual
Jan 23, 2018
Primary completionActual
Mar 28, 2022
CompletionActual
Jul 28, 2025
Results first posted
Sep 20, 2024
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03362502
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Jan 23, 2018
Primary completion
Mar 28, 2022
Completion
Jul 28, 2025
Results posted
Sep 20, 2024
Last update
Sep 15, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion